<p>Founded in 1979, Transgene has transformed itself into a leading personalized cancer vaccine player. Alessandro talks about the transformation, his history in cell therapy and how Europe’s biotech space can rival those of the US and China.</p><p><br></p><p>---</p><p>Learn more about Transgene: <a href="https://bit.ly/tg_flotbio" target="_blank" rel="ugc noopener noreferrer">https://bit.ly/tg_flotbio</a></p><p>---</p><p><br></p><p>⭐️ ABOUT THE SPEAKER</p><p><br></p><p>Alessandro became Transgene’s CEO in 2023 after joining in 2022 as Chairman of the Board of Directors. He also played a key role in Gilead Sciences’ acquisition of Kite Pharma and the regulatory approval of the CAR-T therapy Yescarta. </p><p><br></p><p>🔗 LINKS MENTIONED</p><ul><li>Transgene’s website - <a href="https://www.transgene.fr/⁠" target="_blank" rel="ugc noopener noreferrer">https://www.transgene.fr/</a></li><li>Transgene’s €105 million fundraising - <a href="https://www.globenewswire.com/news-release/2025/11/26/3195422/0/en/Transgene⁠-Successfully-Completes-a-Fundraising-of-c-105-Million.html" target="_blank" rel="ugc noopener noreferrer">https://www.globenewswire.com/news-release/2025/11/26/3195422/0/en/Transgene-Successfully-Completes-a-Fundraising-of-c-105-Million.html</a></li><li>FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma - <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-and-adjuvant-pembrolizumab-resectable-locally-advanced-head-and-neck">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-and-adjuvant-pembrolizumab-resectable-locally-advanced-head-and-neck</a></li><li>Gilead Sciences’ acquisition of Kite Pharma for $11.9 billion - <a href="https://www.gilead.com/news/news-details/2017/gilead-sciences-to-acquire-kite-pharma-for-119-billion">https://www.gilead.com/news/news-details/2017/gilead-sciences-to-acquire-kite-pharma-for-119-billion</a></li></ul><ul><ul><li>Johnson &amp; Johnson’s collaboration and license deal withLegend Biotech - <a href="https://www.jnj.com/media-center/press-releases/janssen-enters-worldwide-collaboration-and-license-agreement-with-chinese-company-legend-biotech-to-develop-investigational-car-t-anti-cancer-therapy">https://www.jnj.com/media-center/press-releases/janssen-enters-worldwide-collaboration-and-license-agreement-with-chinese-company-legend-biotech-to-develop-investigational-car-t-anti-cancer-therapy</a></li></ul></ul><p><br></p><p>📜 TRANSCRIPT</p><p><br></p><p>Read the full transcript here: <a href="https://flot.bio/?post_type=episode&p=865" target="_blank" rel="ugc noopener noreferrer">https://flot.bio/episode/alessandro-riva-transgene-cancer-vaccines/</a></p><p><br></p><p>💸 DONATE</p><p><br></p><p>We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: <a href="https://www.paypal.me/PhilipHemme" target="_blank" rel="ugc noopener noreferrer">https://www.paypal.me/PhilipHemme</a></p><p><br></p><p>⭐️ SPONSORSHIP</p><p><br></p><p>Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!</p><p><br></p><p>🫶 FOLLOW US</p><ul><li>Newsletter: <a href="http://eepurl.com/h_fnmH" target="_blank" rel="ugc noopener noreferrer">http://eepurl.com/h_fnmH</a></li><li>LinkedIn: <a href="https://www.linkedin.com/company/flot-bio/" target="_blank" rel="ugc noopener noreferrer">https://www.linkedin.com/company/flot-bio/</a></li><li>X (Twitter): <a href="https://x.com/FlotBio" target="_blank" rel="ugc noopener noreferrer">https://x.com/FlotBio</a></li></ul><p><br></p><p>🙏 LIKE/FOLLOW/REVIEW</p><p><br></p><p>Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.</p><p><br></p><p>🎙️ ABOUT FLOT.BIO</p><p><br></p><p>Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.</p><p><br></p><p>⏰ TIMESTAMPS</p><p><br></p><ul><li>[00:00:00] Intro</li><li>[00:02:02] Transgene, the French biotech heavyweight</li><li>[00:04:55] Standout personalized cancer vaccine</li><li>[00:25:33] Transgene’s €105 million fundraising </li><li>[00:32:05] Catalysts and oncolytic viruses</li><li><br></li><li><br></li><li><br></li><li><br></li><li><br></li></ul><p><br></p>